Stockreport

Evaluating Dianthus Therapeutics (DNTH) Valuation After New DNTH212 Licensing Deal and Pipeline Expansion [Yahoo! Finance]

Dianthus Therapeutics, Inc.  (DNTH) 
PDF DNTH212, a promising autoimmune disease treatment, outside Greater China. The FDA recently cleared this drug candidate for clinical development. See our latest analysi [Read more]